Browsing by Author "Briassoulis, E. Ch"
Now showing items 61-77 of 77
-
Article
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group
Briassoulis, E. Ch; Judson, Ian Robert; Pavlidis, Nicholas; Beale, P.; Wanders, J.; Groot, Y.; Veerman, G.; Schuessler, M.; Niebch, G.; Siamopoulos, K. C.; Tzamakou, E.; Rammou, D.; Wolf, L.; Walker, R.; Hanauske, A. R. (2000)Purpose: To determine the maximum-tolerated dose (MTD), the principal toxicities, and the pharmacokinetics of 6-hour infusion of glufosfamide (beta-D-glucosylisophosphoramide mustard; D-19575), a novel alkylating agent ...
-
Article
Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: Parallel topotecan escalation in two fixed platinum dosing schemes
Pentheroudakis, George; Briassoulis, E. Ch; Karavasilis, V.; Mauri, D.; Tzamakou, E.; Rammou, D.; Pavlidis, Nicholas (2005)Purpose: We performed a phase I study of two fixed dosing schemes of cisplatin, a DNA cross-linker, with intravenous escalating topotecan, a DNA-topoisomerase I inhibitor. Experimental Design: 40 patients with advanced ...
-
Article
Phase i trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: A hellenic cooperative oncology group study
Briassoulis, E. Ch; Golfinopoulos, Vassilis; Karina, M.; Papakostas, P.; Pavlidis, Nicholas; Fountzilas, George (2010)This trial aimed to define a recommended safe dose (RSD) of weekly paclitaxel and irinotecan combined with carboplatin in patients with advanced cancer. Patients with advanced cancer were eligible for this trial. Dose-limiting ...
-
Article
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG
Joerger, M.; Huitema, A. D. R.; Richel, D. J.; Dittrich, C.; Pavlidis, Nicholas; Briassoulis, E. Ch; Vermorken, J. B.; Strocchi, E.; Martoni, A.; Sorio, R.; Sleeboom, H. P.; Izquierdo, M. A.; Jodrell, D. I.; Féty, R.; Bruijn, E. De; Hempel, G.; Karlsson, M.; Tranchand, B.; Schrijvers, A. H. G. J.; Twelves, C.; Beijnen, J. H.; Schellens, J. H. M. (2007)Aims: To investigate the population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients. Patients and methods: Sixty-five female patients with early or advanced breast cancer ...
-
Article
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
Joerger, M.; Huitema, A. D. R.; Richel, D. J.; Dittrich, C.; Pavlidis, Nicholas; Briassoulis, E. Ch; Vermorken, J. B.; Strocchi, E.; Martoni, A.; Sorio, R.; Sleeboom, H. P.; Izquierdo, M. A.; Jodrell, D. I.; Calvert, H.; Boddy, A. V.; Hollema, H.; Féty, R.; Vijgh, W. J. F. Van Der; Hempel, G.; Chatelut, E.; Karlsson, M.; Wilkins, J.; Tranchand, B.; Schrijvers, A. H. G. J.; Twelves, C.; Beijnen, J. H.; Schellens, J. H. M. (2007)Purpose: Paclitaxel and carboplatin are frequently used in advanced ovarian cancer following cytoreductive surgery. Threshold models have been used to predict paclitaxel pharmacokinetic-pharmacodynamics, whereas the time ...
-
Article
Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: A randomized phase III study conducted by the hellenic cooperative oncology group
Fountzilas, George; Zisiadis, A.; Dafni, U.; Konstantaras, C.; Hatzitheoharis, G.; Liaros, A.; Athanassiou, E.; Dombros, N.; Dervenis, C.; Basdanis, G.; Gamvros, O.; Souparis, A.; Briassoulis, E. Ch; Samantas, E.; Kappas, A. M.; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas (1999)Background: Randomized studies have shown that postoperative chemotherapy with or without radiation therapy (RT) improved local control and survival of patients with stages II or III rectal cancer. However, the optimal ...
-
Article
The prognostic evaluation of tumor angiogenesis in invasive breast carcinoma
Ioachim, E.; Charchanti, A.; Charalabopoulos, K.; Tsanou, E.; Briassoulis, E. Ch; Karavasilis, V.; Pavlidis, Nicholas; Agnantis, Niki J. (2002)Microvessel density (MVD) was analyzed for associations with clinical and pathological factors as well as with other potential known prognostic factors such as: steroid receptor content (ER, PgR), p53 and proliferation ...
-
Article
Prognostic factors influencing complete response to treatment and survival of patients with nasopharyngeal cancer
Kalogera-Fountzila, Anna; Kosmidis, Paraskevas A.; Bacoyiannis, Charalambos; Nicolaou, A.; Samantas, E.; Briassoulis, E. Ch; Pavlidis, Nicholas; Skarlos, Dimosthenis V.; Daniilidis, J.; Fountzilas, George (1998)The identification of prognostic factors influencing local control and survival of patients with nasopharyngeal cancer (NPC) might help in pointing out those patients who would probably benefit from primary treatment. A ...
-
Article
The prognostic value of vascular endothelial growth factor (VEGF) in invasive breast cancer: Correlation with microvessel density (MVD), ER, PgR, p53 and proliferative associated indices (Ki-67, PCNA)
Ioachim, E.; Charchanti, A.; Briassoulis, E. Ch; Karavasilis, V.; Batsis, Ch; Pavlidis, Nicholas; Agnantis, Niki J. (2002)The formation of new vessels in both primary tumour and in metastasis induce various growth factors included the vascular endothelial growth factors (VEGF). The immunohistochemical expression of vascular endothelial growth ...
-
Article
Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG)
Skarlos, Dimosthenis V.; Samantas, E.; Briassoulis, E. Ch; Panoussaki, E.; Pavlidis, Nicholas; Kalofonos, H. P.; Kardamakis, D.; Tsiakopoulos, E.; Kosmidis, Paraskevas A.; Tsavdaridis, D.; Tzitzikas, J.; Tsekeris, P.; Kouvatseas, G.; Zamboglou, N.; Fountzilas, George (2001)Background: Concurrent platinum-etoposide chemotherapy given in combination with hyperfractionated thoracic radiation therapy (HTRT) in limited disease (LD) small cell lung cancer (SCLC) is associated with a high response ...
-
Article
A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group Study
Fountzilas, George; Athanasiades, A.; Giannakakis, T.; Briassoulis, E. Ch; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Onienaoum, A.; Kalofonos, H. P.; Pectasides, Dimitrios; Andreopoulou, E.; Bamia, C.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Skarlos, Dimosthenis V. (1997)Purpose: To evaluate the impact on the response rate in patients with advanced breast cancer (ABC) of the doubling of the dose intensity (DI) of epirubicin monotherapy. Patients and methods: From January 1991 until April ...
-
Article
A retrospective analysis of serum CA 15-3 concentrations in patients with localised or metastatic renal cancer and its impact on prognosis and follow-up. A single-centre experience
Briassoulis, E. Ch; Pentheroudakis, George; Letsa, I.; Pavlidis, Nicholas (2002)Background. Monitoring patients with renal cancer for recurrence or progression is ineffective, inconvenient and costly. We conducted a retrospective analysis of serum CA 15-3 concentrations in a single-centre patient ...
-
Article
Second malignancies following treatment for Hodgkin's disease: A Greek experience
Economopoulos, T.; Stathakis, N.; Alexopoulos, C.; Pavlidis, Nicholas; Constantinidou, M.; Briassoulis, E. Ch; Papageorgiou, E.; Dervenoulas, John; Pappa, Vassiliki; Vaslamatzis, M.; Raptis, S. (1994)The risk and the type of second malignancies (SM) developing in 217 treated Hodgkin's disease (HD) patients were studied. The median age of the patients was 35 years (range 14-83) and the M/F ratio 1.8. Treatment consisted ...
-
Article
Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions [1]
Briassoulis, E. Ch; Karavasilis, V.; Pavlidis, Nicholas (2000)
-
Article
The value of CA-125 determination in the serum of patients with non-Hodgkin's lymphomas. A preliminary report
Pavlidis, Nicholas; Bairaktari, Eleni Th; Kalef-Ezra, J. A.; Nikolaides, C.; Briassoulis, E. Ch; Seferiadis, C.; Fountzilas, George (1994)The levels of CA 19-9, CA 15-3 and CA 125 in the serum of 50 patients with non-Hodgkin's lymphomas (NHL) were investigated. Mean values of these serum tumor markers were compared to stage, presence or absence of B-symptoms, ...
-
Article
Weekly docetaxel in minimally pretreated cancer patients: A dose- escalation study focused on feasibility and cumulative toxicity of long-term administration
Briassoulis, E. Ch; Karavasilis, V.; Anastasopoulos, D.; Tzamakou, E.; Fountzilas, George; Rammou, D.; Kostadima, Vasiliki; Pavlidis, Nicholas (1999)Background: Docetaxel is an agent with impressive clinical activity but a rather poor profile of toxicity when given every three weeks. Therefore, optimisation of its clinical use is highly warranted. This is a dose- ...
-
Article
Weekly paclitaxel combined with pegylated liposomal doxorubicin (Caelyx ™) given every 4 weeks: Dose-finding and pharmacokinetic study in patients with advanced solid tumors
Briassoulis, E. Ch; Pentheroudakis, George; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Pavlidis, Nicholas (2004)Background: We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyx™) and weekly paclitaxel (wPTX), and to investigate pharmacokinetics ...